Chengdu Olymvax Biopharmaceuticals Inc. - ROE
688319.SS
Price:
$27.31
Market Cap:
$11.07B
Chengdu Olymvax Biopharmaceuticals Inc. specializes in the research, development, and distribution of vaccines. Their current product portfolio includes immunizations against tetanus, a severe and often fatal infectious disease that damages the nervous system due to toxins produced by Clostridium tetani, alongside a vaccine for Haemophilus influenzae type b. Beyond their existing offerings, the company is actively advancing new vaccine candidates targeting Staphylococcus aureus, a prevalent bacterium responsible for both hospital-acquired and community infections, and illnesses associated with Group A streptococcus. This enterprise was established in 2009 and operates from its base in Chengd...[Read more]
Industry
Biotechnology
IPO Date
2021-06-08
Stock Exchange
SHH
Ticker
688319.SS
PE Ratio
[589.21]
ROE
[-2.60%]
Current Ratio
[1.29]
Dividend Yield
[0%]
Enterprise Value
[11.36B]
Dividend History
The ROE as of September 2026 (TTM) for Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) is -2.60%
According to Chengdu Olymvax Biopharmaceuticals Inc.’s latest financial reports and current stock price. The company's current ROE is -2.60%. This represents a change of 224.27% compared to the average of -0.80% of the last 4 quarters.
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) Historical ROE (quarterly & annually)
How has 688319.SS ROE performed in the past?
The mean historical ROE of Chengdu Olymvax Biopharmaceuticals Inc. over the last ten years is -1.74%. The current -2.60% ROE has changed 49.94% with respect to the historical average. Over the past ten years (40 quarters), 688319.SS's ROE was at its highest in in the September 2020 quarter at 6.13%. The ROE was at its lowest in in the September 2016 quarter at -9.89%.
Average
-1.74%
Median
2.08%
Minimum
-30.79%
Maximum
12.78%
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) ROE by Quarter and Year
Discovering the peaks and valleys of Chengdu Olymvax Biopharmaceuticals Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 33.36%
Maximum Annual ROE = 12.78%
Minimum Annual Increase = -3185.88%
Minimum Annual ROE = -30.79%
| Year | ROE | Change |
|---|---|---|
| 2025 | 2.46% | 9.59% |
| 2024 | 2.24% | 17.25% |
| 2023 | 1.91% | -36.49% |
| 2022 | 3.01% | -76.42% |
| 2021 | 12.78% | 33.36% |
| 2020 | 9.58% | -205.24% |
| 2019 | -9.11% | -6.82% |
| 2018 | -9.77% | -3185.88% |
| 2017 | 0.32% | -101.03% |
| 2016 | -30.79% | 21.68% |
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) Average ROE
How has 688319.SS ROE performed in the past?
The current ROE of Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
2.21%
5-year avg
4.48%
10-year avg
-1.74%
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) ROE vs. Peers
How is 688319.SS’s ROE compared to its peers?
Chengdu Olymvax Biopharmaceuticals Inc.’s ROE is less than Chengzhi Shareholding Co., Ltd. (1.08%), less than Chengdu Kanghua Biological Products Co., Ltd. (6.93%), less than Aurisco Pharmaceutical Co.,Ltd. (14.09%), greater than Youcare Pharmaceutical Group Co., Ltd. (-8.11%), greater than Daan Gene Co., Ltd. (-9.44%), less than Anhui Huaheng Biotechnology Co., Ltd. (4.36%), less than Chengdu Easton Biopharmaceuticals Co., Ltd. (9.46%), greater than Nanjing Vazyme Biotech Co., Ltd. (-0.24%), less than Guilin Sanjin Pharmaceutical Co., Ltd. (12.50%), less than Zhejiang Ausun Pharmaceutical Co., Ltd. (3.46%),
| Company | ROE | Market cap |
|---|---|---|
| 1.08% | $11.01B | |
| 6.93% | $6.32B | |
| 14.09% | $7.68B | |
| -8.11% | $5.48B | |
| -9.44% | $7.41B | |
| 4.36% | $4.16B | |
| 9.46% | $7.88B | |
| -0.24% | $10.08B | |
| 12.50% | $7.19B | |
| 3.46% | $6.24B |
Build a custom stock screener for Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Chengdu Olymvax Biopharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Chengdu Olymvax Biopharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Chengdu Olymvax Biopharmaceuticals Inc.'s ROE?
How is the ROE calculated for Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)?
What is the highest ROE for Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)?
What is the 3-year average ROE for Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)?
What is the 5-year average ROE for Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)?
How does the current ROE for Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS) compare to its historical average?